Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.
October 30, 2014
Verastem Reports Third Quarter 2014 Financial and Corporate Results
October 24, 2014
Verastem Presents New Data on Mesothelioma Programs at the 12th International Mesothelioma Interest Group Meeting
October 8, 2014
Verastem to Present New Data at the 12th International Mesothelioma Interest Group Conference
The majority of cancer drugs, while killing the bulk of tumor cells, ultimately fail to induce durable clinical responses. A reason for this failure may be the presence of a minority of cells in the tumor called cancer stem cells which are resistant to existing cancer therapies.
Using our proprietary technology we are identifying and developing drugs that target and kill cancer stem cells.